Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Net Income (2023 - 2025)

Monte Rosa Therapeutics' Net Income history spans 3 years, with the latest figure at -$46.1 million for Q4 2025.

  • For Q4 2025, Net Income fell 173.39% year-over-year to -$46.1 million; the TTM value through Dec 2025 reached -$38.6 million, down 65.81%, while the annual FY2025 figure was -$38.6 million, 65.93% down from the prior year.
  • Net Income reached -$46.1 million in Q4 2025 per GLUE's latest filing, down from -$27.1 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $62.9 million in Q4 2024 to a low of -$46.1 million in Q4 2025.
  • Average Net Income over 3 years is -$16.4 million, with a median of -$31.1 million recorded in 2024.
  • Peak YoY movement for Net Income: soared 289.04% in 2024, then crashed 173.39% in 2025.
  • A 3-year view of Net Income shows it stood at -$33.3 million in 2023, then skyrocketed by 289.04% to $62.9 million in 2024, then tumbled by 173.39% to -$46.1 million in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Net Income are -$46.1 million (Q4 2025), -$27.1 million (Q3 2025), and -$12.3 million (Q2 2025).